Sorrento Therapeutics’ subsidiary Scilex Holding Company acquires rights to acute migraine treatment

pharmafile | February 13, 2023 | News story | Sales and Marketing  

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, has announced that it has acquired the rights to ELYXYBTM (celecoxib oral solution) in the US and Canada.


ELYXYBTM is the only FDA approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. It is formulated using a self-micro emulsifying drug delivery system which improves solubility and bioavailability of the drug, leading to better absorption.


Pivotal studies found that ELYXYBTM had a rapid onset of action, which is vital for migraine sufferers and its unit-dose of oral solution makes it convenient for patient in the event of a migraine attack. Studies with ELYXYBTM also confirmed the efficacy of celecoxib in the treatment of migraines with very few side effects.


“The acquisition of ELYXYB reaffirms Scilex’s commitment to offer innovative, non-opioid pain management products and to develop meaningfully differentiated programs that address significant unmet needs leading to better health outcomes for the millions of acute and chronic pain patients,” commented Henry Ji, PhD, executive chairperson of Scilex and chairman and chief executive officer of Sorrento.


Dr Peter McAllister, medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research and Ki Clinical Research, associate professor of Neurology at the Yale University School of Medicine, New Haven, Connecticut and clinical professor of Neurology and Anatomy at the Frank H. Netter School of Medicine at Quinnipiac University, Hamden, Connecticut said, “I am delighted that liquid celecoxib will remain on the market. It is a very important medication we use to treat migraine, with fast onset and favourable safety and tolerability profile.”


James Spargo

Related Content

No items found

Latest content